Abstract
Radiolabeling of the chemotherapeutic agent BOLD-100 with ruthenium-103 enables animal experiments with lower amounts of injected drug. This leads to a relatively higher tumor uptake and promising tumor-to-background ratio for future imaging studies.
Funding Information
  • Institut National des Sciences de l'Univers, Centre National de la Recherche Scientifique
  • Institut National de la Santé et de la Recherche Médicale
  • Conseil Régional des Pays de la Loire
  • European Commission

This publication has 33 references indexed in Scilit: